Semaglutide

Scientific overview

Semaglutide is a 31-amino-acid GLP-1 receptor agonist analog with a fatty-acid side chain that extends its half-life through albumin binding. Preclinical research focuses on its effects on incretin signaling, gastric-emptying rate, and glucose-dependent insulin secretion pathways.